Literature DB >> 7575533

Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease.

T Okumiya1, S Ishii, T Takenaka, R Kase, S Kamei, H Sakuraba, Y Suzuki.   

Abstract

The effect of galactose on alpha-galactosidase missense mutants causing Fabry disease was investigated in the COS-1 cell expression system and lymphoblasts. Three mutant enzymes, A156V, L166V and Q279E, showed increases in activity and amount in COS-1 cells cultured with galactose. Another mutant without catalytic activity, C142Y, did not show any changes. In lymphoblasts cultured with galactose, the enzyme activity increased significantly in four classical Fabry patients with the respective mutations, A156V, L166V, G260A and G373S, and in three atypical Fabry patients with the respective mutations, Q279E, R301Q and M296I. Such an increase was not observed in the other four classical Fabry patients, with C142Y, E66Q/R112C, G328R and N320K, respectively. This suggests that many missense mutations in the alpha-galactosidase gene causing Fabry disease allow the expression of catalytically active mutant enzymes regardless of the clinical phenotype, which are rapidly degraded under physiological conditions and stabilized by galactose.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575533     DOI: 10.1006/bbrc.1995.2416

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

1.  Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.

Authors:  Fumiko Matsuzawa; Sei-ichi Aikawa; Hirofumi Doi; Toshika Okumiya; Hitoshi Sakuraba
Journal:  Hum Genet       Date:  2005-05-28       Impact factor: 4.132

Review 2.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Authors:  Kenneth J Valenzano; Richie Khanna; Allan C Powe; Robert Boyd; Gary Lee; John J Flanagan; Elfrida R Benjamin
Journal:  Assay Drug Dev Technol       Date:  2011-06       Impact factor: 1.738

Review 3.  Enzyme replacement and beyond.

Authors:  R J Desnick
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

Review 4.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

5.  Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.

Authors:  Jung Young Park; Gu Hwan Kim; Sung Su Kim; Jung Min Ko; Jin Joo Lee; Han Wook Yoo
Journal:  Exp Mol Med       Date:  2009-01-31       Impact factor: 8.718

6.  Functional studies of new GLA gene mutations leading to conformational Fabry disease.

Authors:  C Filoni; A Caciotti; L Carraresi; C Cavicchi; R Parini; D Antuzzi; A Zampetti; S Feriozzi; P Poisetti; S C Garman; R Guerrini; E Zammarchi; M A Donati; A Morrone
Journal:  Biochim Biophys Acta       Date:  2009-11-24

Review 7.  Enzyme replacement and enhancement therapies for lysosomal diseases.

Authors:  R J Desnick
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

8.  The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.

Authors:  E R Benjamin; J J Flanagan; A Schilling; H H Chang; L Agarwal; E Katz; X Wu; C Pine; B Wustman; R J Desnick; D J Lockhart; K J Valenzano
Journal:  J Inherit Metab Dis       Date:  2009-04-18       Impact factor: 4.982

9.  Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.

Authors:  Junichiro Matsuda; Osamu Suzuki; Akihiro Oshima; Yoshie Yamamoto; Akira Noguchi; Kazuhiro Takimoto; Masayuki Itoh; Yuji Matsuzaki; Yosuke Yasuda; Seiichiro Ogawa; Yuko Sakata; Eiji Nanba; Katsumi Higaki; Yoshimi Ogawa; Lika Tominaga; Kousaku Ohno; Hiroyuki Iwasaki; Hiroshi Watanabe; Roscoe O Brady; Yoshiyuki Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

10.  Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities.

Authors:  Yoshiyuki Suzuki; Seiichiro Ogawa; Yasubumi Sakakibara
Journal:  Perspect Medicin Chem       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.